Evimero
Evimero is an interdisciplinary company focused on understanding the interactions between microorganisms and human health, agriculture, and the environment, utilizing Systems Biology and AI/ML. Evimero applies molecular principles to infectious disease and microbiome science to improve health outcomes and environmental sustainability through targeted interventions in dysbiotic microbiomes and in people with infectious disorders. Evimero has an infectious disease product pipeline including both prophylactic and diagnostic assets against common causes of Travelers' Diarrhea, including a unique approach to preventing infection with human Norovirus, enterotoxigenic E. coli (ETEC) and others. Evimero's pipeline of drugs targeting human and animal microbiomes includes early-stage assets aimed at generalized microbiome-driven inflammation and gut leak, and specific disease-targeted disorders including Parkinson Disease and Inflammatory Bowel Diseases. Evimero's platform also makes possible a suite of point-of-care diagnostics that can be used for patient cohorting (infectious diseases), risk stratification, and ultimately informing therapeutic decision-making. The nature of Evimero's platform assures a steady stream of novel assets targeting both infectious diseases and chronic disorders with roots in microbiome dysfunction.
What We Do
A patented technology platform that rapidly discovers key molecules involved in dysbiotic microbiomes and neutralizes their negative effects. It utilizes a Causal Generative Artificial Intelligence (CGAI) framework to create high-resolution maps of microbiome pathways, applicable in healthcare, agriculture, and environmental settings.
A complete solution for rapid response to infectious diseases, from laboratory identification to diagnostic and therapeutic development, significantly reducing development time and costs compared to traditional drug discovery.
Application Area
News & Updates
This article discusses insights from the study of human microbiomes and emerging applied therapeutics.
Research on avian antibodies as a response to the COVID-19 pandemic, focusing on their ability to inhibit SARS-CoV-2.
Feasibility of avian antibodies as prophylaxis against enterotoxigenic escherichia coli colonization
This study evaluates the use of avian immunoglobulins as a preventive measure against ETEC-related diarrheal illness.
Research on the potential of avian antibodies to prevent infections caused by human norovirus, a leading cause of viral diarrhea.